MYD88 Fusion is an inclusion criterion in 1 clinical trial for lymphoproliferative disorder, of which 0 are open and 1 is closed. Of the trial that contains MYD88 Fusion and lymphoproliferative disorder as inclusion criteria, 1 is phase 1 (0 open) [5].

MYD88 Fusion is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYD88 Fusion and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

MYD88 Fusion is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 Fusion and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYD88 Fusion is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 Fusion and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYD88 Fusion is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 Fusion and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYD88 Fusion is an inclusion criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 Fusion and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYD88 Fusion is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 Fusion and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYD88 Fusion is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 0 are open and 1 is closed. Of the trial that contains MYD88 Fusion and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1 (0 open) [5].